94 related articles for article (PubMed ID: 22576694)
1. Influence of resistance to 5-fluorouracil and tomudex on [18F]‑FDG incorporation, glucose transport and hexokinase activity.
Law AA; Collie-Duguid ES; Smith TA
Int J Oncol; 2012 Jul; 41(1):378-82. PubMed ID: 22576694
[TBL] [Abstract][Full Text] [Related]
2. Decreased [18F]fluoro-2-deoxy-d-glucose incorporation and increased glucose transport are associated with resistance to 5FU in MCF7 cells in vitro.
Smith TA; Sharma RI; Wang WG; Welch AE; Schweiger LF; Collie-Duguid ES
Nucl Med Biol; 2007 Nov; 34(8):955-60. PubMed ID: 17998098
[TBL] [Abstract][Full Text] [Related]
3. Colorectal tumor cells treated with 5-FU, oxaliplatin, irinotecan, and cetuximab exhibit changes in 18F-FDG incorporation corresponding to hexokinase activity and glucose transport.
Sharma RI; Smith TA
J Nucl Med; 2008 Aug; 49(8):1386-94. PubMed ID: 18632807
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks.
Wang W; McLeod HL; Cassidy J; Collie-Duguid ES
Cancer Chemother Pharmacol; 2007 May; 59(6):839-45. PubMed ID: 17119966
[TBL] [Abstract][Full Text] [Related]
5. Treatment of SW620 cells with Tomudex and oxaliplatin induces changes in 2-deoxy-D-glucose incorporation associated with modifications in glucose transport.
Smith TA; Maisey NR; Titley JC; Jackson LE; Leach MO; Ronen SM
J Nucl Med; 2000 Oct; 41(10):1753-9. PubMed ID: 11038008
[TBL] [Abstract][Full Text] [Related]
6. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
[TBL] [Abstract][Full Text] [Related]
7. Resistance to tomudex (ZD1694): multifactorial in human breast and colon carcinoma cell lines.
Drake JC; Allegra CJ; Moran RG; Johnston PG
Biochem Pharmacol; 1996 May; 51(10):1349-55. PubMed ID: 8787551
[TBL] [Abstract][Full Text] [Related]
8. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs.
Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558
[TBL] [Abstract][Full Text] [Related]
9. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture.
Aloj L; Caracó C; Jagoda E; Eckelman WC; Neumann RD
Cancer Res; 1999 Sep; 59(18):4709-14. PubMed ID: 10493529
[TBL] [Abstract][Full Text] [Related]
10. Involvement of bcl-2 and p21waf1 proteins in response of human breast cancer cell clones to Tomudex.
Orlandi L; Bearzatto A; Abolafio G; De Marco C; Daidone MG; Zaffaroni N
Br J Cancer; 1999 Sep; 81(2):252-60. PubMed ID: 10496350
[TBL] [Abstract][Full Text] [Related]
11. Treatment of breast tumor cells in vitro with the mitochondrial membrane potential dissipater valinomycin increases 18F-FDG incorporation.
Smith TA; Blaylock MG
J Nucl Med; 2007 Aug; 48(8):1308-12. PubMed ID: 17673425
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance in colon cancer.
Gorlick R; Bertino JR
Semin Oncol; 1999 Dec; 26(6):606-11. PubMed ID: 10606253
[TBL] [Abstract][Full Text] [Related]
13. [18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil.
Suttie SA; Park KG; Smith TA
Br J Cancer; 2007 Oct; 97(7):902-9. PubMed ID: 17848947
[TBL] [Abstract][Full Text] [Related]
14. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines.
Johnston PG; Drake JC; Trepel J; Allegra CJ
Cancer Res; 1992 Aug; 52(16):4306-12. PubMed ID: 1643628
[TBL] [Abstract][Full Text] [Related]
15. Interaction of tomudex with radiation in vitro and in vivo.
Teicher BA; Ara G; Chen YN; Recht A; Coleman CN
Int J Oncol; 1998 Sep; 13(3):437-42. PubMed ID: 9683775
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of 5-fluorouracil on glucose transport and expressions of glucose transporter proteins in gastric cancer cells.
Won HJ; Ha TK; Kwon SJ; Cho HY; Hur SJ; Baik HH; Suh SI; Ha E; Kim YH
Anticancer Drugs; 2010 Mar; 21(3):270-6. PubMed ID: 20023572
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-Induced increase in FDG uptake in MCF7 cells.
Burgman P; Odonoghue JA; Humm JL; Ling CC
J Nucl Med; 2001 Jan; 42(1):170-5. PubMed ID: 11197971
[TBL] [Abstract][Full Text] [Related]
18. Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial.
Ducreux M; Bouche O; Pignon JP; Mousseau M; Raoul JL; Cassan P; Leduc B; Berger C; Dunant A; Fournet J; Bedenne L;
Oncology; 2006; 70(3):222-30. PubMed ID: 16816536
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate.
Li WW; Tong WP; Bertino JR
Clin Cancer Res; 1995 Jun; 1(6):631-6. PubMed ID: 9816025
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia stimulates 18F-fluorodeoxyglucose uptake in breast cancer cells via hypoxia inducible factor-1 and AMP-activated protein kinase.
Smith TA; Zanda M; Fleming IN
Nucl Med Biol; 2013 Aug; 40(6):858-64. PubMed ID: 23786679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
